Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Subscribe To Our Newsletter & Stay Updated
